2487 — Cutia Therapeutics Income Statement
0.000.00%
Last trade - 00:00- HK$1.93bn
- HK$1.34bn
- CNY279.62m
Annual income statement for Cutia Therapeutics, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 2.04 | 11.4 | 138 | 280 |
| Cost of Revenue | ||||
| Gross Profit | 1.61 | 7.94 | 71 | 140 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 321 | 565 | 2,097 | 703 |
| Operating Profit | -319 | -554 | -1,959 | -423 |
| Total Net Non Operating Interest Income / Expense | ||||
| Net Income Before Taxes | -320 | -556 | -1,964 | -434 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -320 | -556 | -1,964 | -434 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -320 | -556 | -1,964 | -434 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -320 | -556 | -1,964 | -434 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -1.05 | -1.75 | -6.38 | -1.41 |
| Dividends per Share |